Although its asymmetric expression may indicate that Oct-4 is a suitable target for therapeutic intervention in adenocarcinoma and bronchioloalveolar carcinoma [15], the role of Oct-4 expression in primary NSCLC has remained ill defined. This evidence concerns the gene POU5F1 and adenocarcinoma.